Core Viewpoint - The company is changing its stock abbreviation from "江中药业" to "华润江中" while maintaining the stock code "600750" effective January 30, 2026, to enhance brand recognition and market influence [2][3][4]. Group 1 - The new stock abbreviation will be "华润江中" and the stock code "600750" will remain unchanged [2][4]. - The decision to change the stock abbreviation was approved during the board meeting on December 12, 2025, and the second extraordinary shareholders' meeting on December 29, 2025 [2]. - The change aims to strengthen brand synergy with 华润 and improve the company's brand recognition and market impact [3].

Core Viewpoint - Jiangzhong Pharmaceutical (600750) has confirmed that its subsidiary, Jiangzhong Decoction Pieces, primarily serves medical institutions in the Jiangxi region, with related business revenue included in the company's consolidated financial statements [1] Group 1 - The company's decoction business is focused on the Jiangxi region [1] - The brand "Huizhongtang" under Jiangzhong Decoction Pieces has multiple products that have been selected as "Traditional Chinese Medicine Decoction Brand Products" [1] - Currently, the company does not have any overseas business operations [1]

Group 1 - The number of listed companies disclosing data is steadily increasing, indicating a sign of maturity in China's nutrition and health industry [1] Group 2 - Dongpeng Beverage (09980.HK) has announced a global offering of 40.89 million shares, with 4.09 million shares available in Hong Kong and 36.80 million shares for international offering, along with an over-allotment option of 6.13 million shares. The subscription period is from January 26 to January 29, with an expected listing date on February 3 [2] - Jiangzhong Pharmaceutical aims for a net profit of 900 million yuan by 2025 [3] - Angel Yeast plans to invest in a green manufacturing project for yeast products [3] - Ningbo Yujian Health Technology Co., Ltd., a dietary supplement raw material manufacturer, is pursuing a listing on the Beijing Stock Exchange, with continuous growth in revenue and net profit projected from 2022 to 2025 [3]

Group 1 - Multiple heavyweight stocks experienced significant sell orders at the close, with Zijin Mining's sell order amount exceeding 4 billion yuan [1] - The head of broad-based ETFs has seen a continuous reduction in shares, with the average share reduction of 27.24% for six large-scale ETFs over the past seven trading days [1] - The CSI 1000 ETFs have seen a dramatic decline, with an average share reduction of 47.9% over the same period, and two products experiencing a drop of over 50% [1] Group 2 - The Dalian Commodity Exchange announced the listing parameters for soybean meal and corn options, set to begin trading on February 2 [2] - The international gold price has reached a new high, with spot gold surpassing 5,100 USD per ounce, leading to a rise in gold jewelry prices in Shenzhen [3] - The global laptop shipment is expected to decrease by 14.8% in Q1 2026 due to rising prices of CPUs and memory [4] Group 3 - The global production of lithium iron phosphate is projected to reach 70,000 tons by 2026, up from 28,500 tons in 2025, driven by demand in electric vehicles and consumer electronics [4] - SoftBank has terminated negotiations to acquire data center operator Switch, impacting its AI infrastructure ambitions [5] - Porsche plans to reduce its dealer network by 30% this year, with no current plans for local production in China [5] Group 4 - Hunan Gold plans to integrate gold mines, expecting to add approximately 4 tons of gold reserves upon reaching production capacity [7] - The stock of *ST Tianshan may face delisting due to projected losses of 16 million to 23 million yuan for 2025 [9] - Jiangzhong Pharmaceutical will change its stock name to "China Resources Jiangzhong" to enhance brand recognition [10] Group 5 - Changyuan Donggu received a notice of being selected as a supplier for a well-known domestic passenger car project, with an estimated sales amount of 2.2 billion to 3 billion yuan [11] - Shankai Intelligent won a project for developing a smart water service platform, with a bid amount of 12.11 million yuan [12] - Several companies, including Koli Yuan and Shenling Environment, forecast significant profit increases for 2025, with expected growth rates ranging from 49.69% to 420% [13][14][15][17][19]

Group 1: Profit Forecasts - Shenling Environment expects a net profit of 205 million to 246 million yuan for 2025, representing a year-on-year increase of 77.39% to 112.87% [1] - Meinuohua anticipates a net profit of 100 million to 123 million yuan for 2025, an increase of 49.69% to 84.11% compared to the previous year [2] - Suotong Development forecasts a net profit of 730 million to 850 million yuan for 2025, reflecting a year-on-year increase of 167.98% to 212.03% [3] - Aikelan projects a net profit of 75 million to 100 million yuan for 2025, indicating a growth of 50.37% to 100.49% [3] - Hengyu Environmental expects a net profit of approximately 35.56 million yuan for 2025, a year-on-year increase of about 104.14% [4] - Yixin Tang anticipates a net profit of 260 million to 330 million yuan for 2025, representing a growth of 127.79% to 189.12% [6] - Yinlong Co. expects a net profit increase of 40% to 60%, projecting 331 million to 379 million yuan for 2025 [12] - Beite Technology forecasts a net profit of 11.5 million to 12.5 million yuan for 2025, reflecting a year-on-year increase of 60.98% to 74.98% [14] - Ha Li Co. anticipates a net profit of 65 million to 78 million yuan for 2025, representing a growth of 92% to 130% [33] - Ji Xin Technology expects a net profit of 115 million to 169 million yuan for 2025, indicating an increase of 277.15% to 454.09% [48] Group 2: Loss Forecasts - Chip Source Micro anticipates a net profit decrease of 62.53% to 74.36%, projecting 52 million to 76 million yuan for 2025 [8] - Lanhua Ketech expects a net loss of 440 million to 550 million yuan for 2025, indicating a shift from profit to loss compared to the previous year [13] - *ST Tianshan forecasts a net loss of 16 million to 23 million yuan for 2025, potentially triggering financial delisting [18] - Pingao Co. anticipates a net loss of 54 million to 44 million yuan for 2025, although this represents a narrowing of losses compared to the previous year [19] - Jianglong Boat expects a net loss of 90 million to 120 million yuan for 2025, a significant decline from the previous year's profit of 11.25 million yuan [20] - Li Guo Chemical anticipates a net loss of 410 million to 480 million yuan for 2025 [21] - Weichuan Technology expects a net loss of 110 million to 140 million yuan for 2025, although this reflects a narrowing of losses compared to the previous year [42] Group 3: Other Notable Announcements - Wan Tai Bio's bivalent HPV vaccine passed the WHO PQ periodic review, aiding its international market expansion [7] - Xian Da Co. received a supplier designation from a well-known international automotive manufacturer [47] - Heng Rui Pharmaceutical received clinical trial approval for its SHR-1049 injection, an innovative anti-tumor drug [15] - Qian Jin Pharmaceutical's subsidiary obtained a drug registration certificate for aluminum magnesium carbonate chewable tablets [16] - New Nuo Wei's subsidiary SYS6090 injection received clinical trial approval, targeting advanced solid tumors [36]

证券代码：600750 证券简称：江中药业 公告编号：2026-004 华润江中药业股份有限公司 证券简称变更实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、公司董事会审议变更证券简称的情况 华润江中药业股份有限公司（以下简称"公司"）于 2025 年 12 月 12 日召开 第十届董事会第十次会议、于 2025 年 12 月 29 日召开了 2025 年第二次临时股东 大会，审议通过了《关于变更公司名称及证券简称、变更注册资本、取消监事会 并修订<公司章程>的议案》，同意公司将证券简称由"江中药业"变更为"华润江 中"，证券代码仍然为"600750"。 二、公司董事会关于变更证券简称的理由 本次变更公司证券简称有助于强化与华润的品牌协同认知，进一步提升公司 品牌辨识度和市场影响力。该事项不会对公司产生重大影响。 三、公司证券简称变更的实施 经公司申请，并经上海证券交易所办理，公司证券简称将于 2026 年 1 月 30 日起由"江中药业"变更为"华润江中"，公司证券代码"600750"保持不变。 特此公告。 华 ...

Core Viewpoint - Jiangzhong Pharmaceutical (600750.SH) will change its stock name to "China Resources Jiangzhong" effective January 30, 2026, while the stock code "600750" will remain unchanged [1]. Group 1 - The company has applied for the name change and it has been processed by the Shanghai Stock Exchange [1].

Group 1 - The company Jiangzhong Pharmaceutical (stock code 600750) will change its stock name to "China Resources Jiangzhong" starting from January 30, 2026, while the stock code will remain the same [1] - This name change aims to enhance brand synergy recognition with China Resources, further improving the company's brand visibility and market influence [1]

Core Viewpoint - The report focuses on the investment opportunities in AI applications, commercial aerospace, and nuclear fusion for 2026, highlighting the performance of the Dividend Low Volatility ETF (512890) amidst a mixed market environment [1][7]. Market Performance - On January 26, A-shares showed mixed results with the Shanghai Composite Index up by 0.12%, while the Shenzhen Component and ChiNext Index experienced declines [1][7]. - The Dividend Low Volatility ETF (512890) rose by 0.52%, closing at 1.154 yuan, with a turnover rate of 1.61% and a transaction volume of 449 million yuan [1][7]. Fund Holdings - The latest quarterly report indicates a mixed performance among the top ten holdings of the Dividend Low Volatility ETF. Notable movements include Shanghai Bank down by 0.21%, Nanjing Bank up by 1.35%, and Gree Electric down by 0.58% [2][9]. - The specific holdings and their market values are as follows: - Shanghai Bank: 781.92 million yuan - Nanjing Bank: 747.01 million yuan (up 32.82%) - Ping An Bank: 712.31 million yuan - Agricultural Bank of Shanghai: 704.49 million yuan - China National Sugar: 690.55 million yuan (down 7.95%) [9]. Fund Flow - The Dividend Low Volatility ETF has seen significant net inflows, with 1.34 billion yuan over the last 5 trading days, 1.88 billion yuan over the last 20 days, and 4.39 billion yuan over the last 60 days. As of January 23, 2026, the fund's circulation scale was 27.845 billion yuan [9]. Investment Strategy - Analysts suggest that the current liquidity environment is a key driver for the spring market rally, supported by new insurance premiums, maturing deposits, and the appreciation of the RMB attracting foreign capital [4][11]. - The report emphasizes the importance of focusing on sectors with strong earnings performance and relatively low price increases, such as AI hardware, batteries, pharmaceuticals, steel, and non-bank financials [11]. - The Dividend Low Volatility strategy is seen as a robust tool for asset allocation in volatile markets, with a three-year return of 36.01%, outperforming its benchmark [12].

Core Viewpoint - Jiangzhong Pharmaceutical reported a revenue of 4.22 billion yuan, a year-on-year decrease of 4.87%, while the net profit attributable to shareholders increased by 14.96% to 906 million yuan [1] Group 1: Financial Performance - The company achieved an operating income of 4.22 billion yuan, reflecting a decline of 4.87% compared to the previous year [1] - The net profit attributable to shareholders reached 906 million yuan, showing a growth of 14.96% year-on-year [1] Group 2: Strategic Measures - The company faced structural adjustment pressures within the industry during the reporting period [1] - To enhance profitability, the company implemented measures such as strengthening brand development and optimizing cost structure [1]